We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01648751
Recruitment Status : Recruiting
First Posted : July 24, 2012
Last Update Posted : December 12, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
This is a randomized controlled trial in which women with symptomatic mild pelvic organ prolapse undergoing Pelvic Floor Physical Therapy (PFPT) receive vaginal estrogen versus placebo to see if a combined approach to treatment leads to improvement in clinical outcomes. The investigators predict that PFPT in combination with vaginal estrogen will lead to decreased pelvic floor symptoms and improved anatomical support corroborated by biomarker data.

Condition or disease Intervention/treatment
Pelvic Organ Prolapse Drug: Vaginal estrogen Drug: Placebo

Detailed Description:
The pathogenesis of pelvic organ prolapse (POP) is unknown. Few studies have correlated patient symptoms and amount of prolapse with biomarkers. POP has traditionally been managed with a pessary or surgery. Recent studies suggest a reduction in POP symptoms following Pelvic Floor Physical Therapy (PFPT). Vaginally delivered hormones are also commonly used to treat prolapse symptoms, with little evidence supporting a clinical benefit. The investigators hypothesize that the optimal approach to improving prolapse symptoms in the patient with mild prolapse requires re-alignment and strengthening of levator muscles via PFPT, and optimization of tissue integrity via local estrogen therapy. The investigators propose to test this hypothesis in a randomized controlled trial in which women with symptomatic mild prolapse opting for PFPT, receive treatment with PFPT in combination with vaginal estrogen versus placebo. The investigators predict that the combined approach will lead to decreased symptoms and improved anatomical support corroborated by biomarker data.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 53 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Impact of Vaginal Estrogen in the Treatment of Symptomatic Mild Pelvic Organ Prolapse With Pelvic Floor Physical Therapy
Study Start Date : May 2012
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Vaginal estrogen
Patients in the experimental group will receive vaginal estrogen cream
Drug: Vaginal estrogen
1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
Other Name: Premarin vaginal cream
Placebo Comparator: Placebo cream
Patients in the comparison group will receive placebo vaginal cream
Drug: Placebo
1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
Other Name: Placebo cream

Outcome Measures

Primary Outcome Measures :
  1. Global impression of improvement in prolapse symptoms, using the PGI-I [ Time Frame: 6 months ]
    To determine the impact of vaginally delivered estrogen on global impression of improvement in women with symptomatic mild pelvic organ prolapse who are undergoing pelvic floor physical therapy

Secondary Outcome Measures :
  1. Pelvic floor symptoms, using the PFDI-20 [ Time Frame: 6 months ]
  2. Quality of life, using the PFIQ-7 [ Time Frame: 6 months ]
  3. Sexual function, using the PISQ-12 [ Time Frame: 6 months ]
  4. Pelvic organ prolapse stage, using the POP-Q exam [ Time Frame: 6 months ]
  5. Collagenase activity [ Time Frame: 6 months ]
    Vaginal swabs collected from the posterior fornix will be used for biochemical analysis

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women in good health aged 40-80
  • Has symptoms of pelvic organ prolapse; answers yes to at least 1 of the following questions:

Do you feel or see a vaginal bulge? Do you feel pressure in the vagina?

  • Meets POP-Q criteria on exam for stage I, II, or III prolapse
  • Interested in PFPT for management of POP
  • Normal mammogram within 1 year of enrollment

Exclusion Criteria:

  • Prior surgery for prolapse or incontinence
  • Other prior interventions for prolapse (e.g. pessary, PFPT)
  • Previous bilateral salpingo-oophorectomy (women with 1 ovary will be eligible)
  • Known liver dysfunction
  • Connective tissue diseases known to affect collagen or elastin remodeling (including: Lupus, Rheumatoid Arthritis, Scleroderma, Sjogrens syndrome, Marfan syndrome, and Ehlers-Danlos syndrome)
  • Unevaluated abnormal vaginal bleeding or abnormal pap smear in the previous year
  • BMI > 35 kg/m2
  • Estrogen therapy (including birth control) in the previous year
  • Current or prior breast or pelvic malignancy (ovarian, tubal, uterine, cervical or vaginal)
  • Contraindication to hormone use (i.e. thromboembolic disorder, use of anti-coagulants, coronary artery disease, history of stroke)
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01648751

Contact: Laura C Skoczylas, MD, MS 323-857-2238 lauraskoczylas@gmail.com
Contact: Pamela Moalli, MD, PhD moalpa@mail.magee.edu

United States, Pennsylvania
Magee-Womens Hospital, University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Lori Geraci, BS    412-641-2634      
Sub-Investigator: Laura C Skoczylas, MD, MS         
Principal Investigator: Pamela Moalli, MD, PhD         
Sponsors and Collaborators
Pamela Moalli
American Urogynecologic Society
National Institutes of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Study Director: Laura C Skoczylas, MD, MS University of Pittsburgh
Principal Investigator: Pamela Moalli, MD, PhD University of Pittsburgh
More Information

Responsible Party: Pamela Moalli, Associate Professor, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT01648751     History of Changes
Other Study ID Numbers: PRO09090064
R01HD061811 ( U.S. NIH Grant/Contract )
First Posted: July 24, 2012    Key Record Dates
Last Update Posted: December 12, 2017
Last Verified: December 2017

Keywords provided by Pamela Moalli, University of Pittsburgh:
Pelvic organ prolapse
Pelvic floor physical therapy
Vaginal estrogen

Additional relevant MeSH terms:
Pelvic Organ Prolapse
Pathological Conditions, Anatomical
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs